Table 2 Key secondary endpoints: rates of CDAI and SDAI LDA and remission, ACR responses, improvements in HAQ-DI (primary analysis set; LOCF imputation)
Placebo-etanercept (N = 104) | Etanercept-etanercept (N = 106) | |
|---|---|---|
CDAI LDA (score ≤10), n (%) | ||
Week 2 | 9 (9.1) | 13 (12.3) |
Week 8 | 16 (15.4) | 31 (29.2) |
Week 12 | 22 (21.2) | 27 (25.5) |
Week 24 | 43 (41.3) | 49 (46.2) |
CDAI remission (score ≤2.8), n (%) | ||
Week 2 | 1 (1.0) | 2 (1.9) |
Week 8 | 0 (0.0) | 3 (2.8) |
Week 12 | 1 (1.0) | 4 (3.8) |
Week 24 | 4 (3.8) | 9 (8.5) |
SDAI LDA (score ≤11), n (%) | ||
Week 2 | 8 (8.2) | 13 (12.4) |
Week 8 | 15 (14.4) | 32 (30.2) |
Week 12 | 22 (21.2) | 25 (23.6) |
Week 24 | 41 (39.4) | 48 (45.3) |
SDAI remission (score ≤3.3), n (%) | ||
Week 2 | 1 (1.0) | 1 (1.0) |
Week 8 | 0 (0.0) | 6 (5.7) |
Week 12 | 2 (1.9) | 6 (5.7) |
Week 24 | 7 (6.7) | 11 (10.4) |
ACR20 response, n (%) | ||
Week 2 | 15 (14.9) | 30 (28.6) |
Week 8 | 24 (23.1) | 53 (50.0) |
Week 12 | 30 (28.8) | 43 (40.6) |
Week 24 | 48 (46.2) | 53 (50.0) |
ACR50 response, n (%) | ||
Week 2 | 3 (3.0) | 6 (5.7) |
Week 8 | 5 (4.8) | 21 (19.8) |
Week 12 | 13 (12.5) | 22 (20.8) |
Week 24 | 30 (28.8) | 35 (33.0) |
ACR70 response, n (%) | ||
Week 2 | 0 (0.0) | 2 (1.9) |
Week 8 | 0 (0.0) | 6 (5.7) |
Week 12 | 1 (1.0) | 6 (5.7) |
Week 24 | 13 (12.5) | 17 (16.0) |
Change from baseline in HAQ-DI, mean score change (SD) | ||
Week 2 | −0.09 (0.39) | −0.27 (0.43) |
Week 8 | −0.21 (0.42) | −0.37 (0.47) |
Week 12 | −0.20 (0.43) | −0.39 (0.54) |
Week 24 | −0.45 (0.52) | −0.48 (0.58) |